Discover
ABCL
AbCellera Biologics Inc.
7.10
2 x 5.46
2 x 9.01
bid
ask
-
0.59
7.67%
2 @ 07:53 PM
7.09 -0.01 (0.14%)
| Ytd | 107.60% | |
| 1y | 82.52% |
7.04
day range
7.69
2.75
52 week range
8.44
| Open | 7.39 | Prev Close | 7.69 | Low | 7.04 | High | 7.69 | Mkt Cap | 2.17B |
| Vol | 9.37M | Avg Vol | 7.85M | EPS | -0.48 | P/E | N/A | Forward P/E | -9.86 |
| Beta | 1.15 | Short Ratio | 6.05 | Inst. Own | 42.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 5.50 | 200-d Avg | 4.41 | 1yr Est | 10.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-11 | 2026-03 | 0 | N/A | N/A | N/A |
| 2026-02-24 | 2025-12 | 0 | N/A | 0.15 | 83.33% |
| 2025-11-06 | 2025-09 | 0 | N/A | -0.02 | -11.76% |
| 2025-11-06 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-07 | 2025-06 | 0 | N/A | 0.05 | 29.41% |
| 2025-08-07 | 2025-06 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-07 | Benchmark | Upgrade | Hold | Buy |
| 2026-05-05 | Cantor Fitzgerald | Upgrade | Overweight | |
| 2026-04-10 | Jones Trading | Upgrade | Buy | |
| 2025-11-07 | Leerink Partners | Downgrade | Outperform | Market Perform |
| 2025-08-08 | Stifel | Upgrade | Buy | Buy |
| 2025-07-14 | Keybanc | Upgrade | Overweight | Overweight |
Profile
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-02 | BOOTH ANDREW | Chief Financial Officer | 576.56K | Conversion of Exercise of derivative security |
| 2024-11-24 | HANSEN CARL L.G. | Chief Executive Officer | 56.98M | Conversion of Exercise of derivative security |
| 2026-05-13 | MONTALBANO JOHN S. | Director | 246.00K | Purchase |
| 2026-02-26 | THERMOPYLAE HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | 56.13M | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Baker Bros. Advisors, LP | 30.28M | 214.96M | 9.91% |
| 2026-03-30 | Capital World Investors | 13.36M | 94.86M | 4.38% |
| 2026-03-30 | Two Sigma Investments, LP | 10.56M | 74.99M | 3.46% |
| 2026-03-30 | TD Waterhouse Canada Inc. | 9.56M | 67.91M | 3.13% |
| 2026-03-30 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 7.58M | 53.79M | 2.48% |
| 2026-03-30 | UBS Group AG | 4.21M | 29.88M | 1.38% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | SmallCap World Fund Inc | 13.36M | 94.86M | 4.38% |
| 2026-05-30 | iShares Trust-iShares Biotechnology ETF | 1.71M | 12.16M | 0.56% |
| 2026-05-30 | SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Developed World ex-US E | 564.32K | 4.01M | 0.18% |
| 2026-05-30 | iShares Trust-iShares Genomics Immunology and Healthcare ETF | 412.63K | 2.93M | 0.14% |
| 2026-02-27 | BlackRock Funds-BlackRock Advantage Small Cap Core Fund | 340.52K | 2.42M | 0.11% |
| 2026-03-30 | Driehaus Mutual Funds-Driehaus Micro Cap Growth Fund | 249.24K | 1.77M | 0.08% |